Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Finn et al. (Mon,) studied this question.

www.synapsesocial.com/papers/69d8e7a113e0539d74bedff0 — DOI: https://doi.org/10.1200/jco.20.00808

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Hepatocellular Carcinoma.· 1977 · 2,096 citations
2. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition· 2007 · 545 citations
3. Immunological landscape and immunotherapy of hepatocellular carcinoma· 2015 · 564 citations
4. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial· 2018 · 5,401 citations
5. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma· 2016 · 344 citations